Novel imidazopyridine suppresses STAT3 activation by targeting SHP-1

Area of Science:

• Oncology
• Molecular Biology
• Medicinal Chemistry

Background:

• Unregulated Signal Transducer and Activator of Transcription 3 (STAT3) activation is prevalent in many cancers, promoting tumor growth, migration, and invasion.
• STAT3 activation at tyrosine 705 is triggered by cytokines, growth factors, and hormones, making it a key therapeutic target.

Purpose of the Study:

• To synthesize and evaluate novel imidazopyridine compounds for their potential to inhibit STAT3 phosphorylation at tyrosine 705.
• To assess the impact of these compounds on downstream signaling pathways and cancer cell survival, specifically in hepatocellular carcinoma (HCC).

Main Methods:

• Synthesis of novel imidazopyridine compounds.
• In vitro assays to measure STAT3 phosphorylation at tyrosine 705.
• Analysis of downstream signaling cascades.
• Assessment of hepatocellular carcinoma (HCC) cell survival and proliferation.

Main Results:

• Compound 16 demonstrated significant reduction in phospho-STAT3 levels.
• The compound effectively inhibited downstream signaling pathways.
• Compound 16 attenuated the survival of hepatocellular carcinoma (HCC) cells.
• Further investigation revealed that compound 16 up-regulates protein tyrosine phosphatase SHP-1, leading to reduced STAT3 phosphorylation at tyrosine 705.

Conclusions:

• Novel imidazopyridine compounds, particularly compound 16, show promise as inhibitors of STAT3 signaling.
• Compound 16's mechanism involves the up-regulation of SHP-1, leading to decreased STAT3 activity and reduced HCC cell survival.
• These findings suggest potential therapeutic applications for compound 16 in treating STAT3-dependent cancers like HCC.